Health Care • Biotechnology: Pharmaceutical Preparations
$2.14 ▲ +0.04
(+1.91%)
MKT CAP: $416.3M • VOL: 2.68M
52W L $2 52W H $6
ALT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $41.0K | $20.0K | $426.0K |
| YoY Revenue Growth % | +105.0% | -95.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$94.5M | -$103.2M | -$95.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$88.1M | -$95.1M | -$88.4M |
| EBITDA (Normalized) | -$94.5M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$67.5M | -$79.8M | -$75.8M |
| Capital Expenditures (CapEx) | $11.0K | — | — |
| Free Cash Flow (FCF) | -$67.5M | -$79.8M | -$75.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -34.7% | -45.0% | — |
| Cash & Short-Term Equivalents | $43.8M | $36.9M | — |
| Total Debt (Short + Long Term) | $34.3M | — | — |
| Total Stockholders' Equity | $224.9M | $123.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALT.